Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

Market Cap	9.60M +37.3%
Revenue (ttm)	1.74M +31.9%
Net Income	6.27M
EPS	0.35
Shares Out	18.12M
PE Ratio	1.53
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,248
Average Volume	56,303
Open	0.5580
Previous Close	0.5500
Day's Range	0.5060 - 0.5580
52-Week Range	0.2800 - 0.9200
Beta	-0.47
RSI	47.34
Earnings Date	Apr 20, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 14
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALOPM

Financial Performance

In 2024, EPA:ALOPM's revenue was 1.64 million, a decrease of -6.02% compared to the previous year's 1.74 million. Losses were -7.21 million, -10.89% less than in 2023.